Recent Indian patent rulings, as well as those to come, are changing the intellectual property rights (IPR) landscape for emerging economies. They are watched with keen interest by other developing nations to measure the response of innovative pharmaceutical firms and the global community. Whether or not they are precedent-setting remains to be seen. Reflecting on the … Continue reading Guest column : Indian patent rulings and impact on emerging economies
Month: February 2013
The Y K Hamied Interview : Part Three
On February 6, Cipla announced that its chairman and managing director Yusuf Hamied would step down as managing director, as of March 31, four decades after he assumed the role following the demise of his father and Cipla founder K A Hamied. He will continue as non-executive chairman. In this conversation, Hamied makes known his rarely-expressed … Continue reading The Y K Hamied Interview : Part Three
The Y K Hamied Interview : Part Two
As India considers granting more compulsory licences on patented drugs to improve reach and affordability some experts have predicted more voluntary licensing deals - where the innovator voluntarily gives a licence to a generic company to sell its product and hopes to avoid a compulsory licence. Cipla, a leading patent challenger in India, has yet … Continue reading The Y K Hamied Interview : Part Two
The Y K Hamied Interview : Part One
On January 29, Yusuf Khwaja Hamied, 75, chairman of India’s third-largest drug maker Cipla, and the Grand Old Man of the Indian pharmaceuticals industry, sat down with Gauri Kamath at Cipla’s Mumbai headquarters for a wide-rangeing interview. The energetic Hamied was in his element, answering questions patiently and holding forth on a variety of issues … Continue reading The Y K Hamied Interview : Part One
Guest column: Indian patent rulings and the IPR ecosystem
The uncertainty surrounding the grounds on which compulsory licenses on patented drugs may be granted and lengthy legal proceedings endanger the vitality of the Indian intellectual property (IP) environment. An even greater threat, perhaps the greatest, is the uncertainty surrounding biologic drugs. On what grounds? Significant uncertainty surrounds the grounds on which the Indian government … Continue reading Guest column: Indian patent rulings and the IPR ecosystem
Apothecurry 